ADMA Stock: Price, Earnings History and SEC Filings
ADMA Biologics, Inc. (ADMA) last traded at $11.41, down 2.89% on the latest session and up 13.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.16 against an analyst estimate of $0.16, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ADMA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.16 | $0.16 | +0.00% |
| Sep 2025 | Nov 5, 2025 | $0.16 | $0.16 | +0.00% |
ADMA beat the analyst EPS estimate in 0 of its last 2 reported quarters. Source: Nasdaq.
How ADMA reacts to earnings
Across its last 8 earnings releases, ADMA moved 8.0% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +8.64% |
| 2026-05-06 | After close | -15.97% |
| 2026-02-25 | After close | -3.19% |
| 2026-01-12 | Before open | -0.11% |
| 2025-11-05 | After close | -8.72% |
| 2025-08-06 | After close | -9.65% |
| 2025-05-07 | After close | -10.21% |
| 2025-03-03 | After close | +7.45% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ADMA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $510M | $147M | $28M | 28.8% | $0.60 |
| 2024 | $426M | $198M | $110M | 46.4% | $0.81 |
| 2023 | $258M | -$28M | $4M | -10.9% | $-0.13 |
| 2022 | $154M | -$66M | -$73M | -42.8% | $-0.33 |
| 2021 | $81M | -$72M | -$126M | -88.5% | $-0.51 |
| 2020 | $42M | -$76M | -$115M | -179.4% | $-0.88 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ADMA
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 2, 2026Shareholder vote
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- 8-K · May 4, 2026Other events, Financial statements and exhibits
- DEF 14A · Apr 15, 2026
- 8-K · Mar 27, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Mar 2, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 10-K · Feb 25, 2026
Insider filing activity
ADMA insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ADMA news
- GeneDx Holdings And 2 Other Top Healthcare StocksOct 31, 2026 · finance.yahoo.com
- Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to NoteOct 30, 2026 · finance.yahoo.com
- Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a BetOct 29, 2026 · finance.yahoo.com
- Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to KnowOct 29, 2026 · finance.yahoo.com
- Which Is a Better Investment, ADMA Biologics, Inc. or Vir Biotechnology, Inc. Stock?Oct 28, 2026 · aaii.com
- ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026Oct 28, 2026 · finance.yahoo.com
- Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth KnowingOct 20, 2026 · finance.yahoo.com
About ADMA Biologics, Inc.
ADMA Biologics, Inc. (ADMA) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.